Under construction – not a live service
Sign in
Enrolling by invitationNo phase

A blood test to find heart failure in people taking water tablets

Tests NT-proBNP blood screening for undiagnosed heart failure in adults taking loop diuretics.

Plain-language title generated from the registry record
Registry title: Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey

Key facts

Where
Saint Helier, JerseySee the site

Where in Jersey

  • Jersey General HospitalSaint Helier, JerseyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Government of Jersey
Trial code
NCT07320677
Record updated
6 January 2026
Original description
The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure.Read full original descriptionShow less

Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND-HF LOOP)

The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure.

The main questions it aims to answer are:

1. Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care? 2. Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease?

This is a cluster randomised controlled trial, which means that whole GP practices, rather than individual patients, are randomly assigned to one of two approaches:

1. NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test 2. Usual care, in which patients continue to be managed as they normally would without proactive screening

Participants will:

Be identified from GP records if they are prescribed loop diuretics and have no prior diagnosis of heart failure

In screening practices, be invited to attend for a free finger-prick NT-proBNP blood test and brief questionnaire

Be referred to the heart failure team and invited for an echocardiogram (a heart ultrasound scan) and further assessment if their NT-proBNP level is higher than 125 pg/mL

Researchers will compare outcomes between screening and usual-care practices after 12 months, focusing on new diagnoses of heart failure. They will also look at other important cardiovascular findings, such as new arrhythmias, valve disease, and heart failure hospitalisation rates.

Inclusion: Receiving a loop diuretic (furosemide, bumetanide or torsemide); No coded diagnosis of heart failure in GP records; Never had a natriuretic peptide test; Willing to have a blood test for NT-proBNP.

Exclusion: Prior diagnosis of heart failure; Prior natriuretic peptide testing; Clinical Frailty Score 7 or above on Rockwood frailty scale.

ClinicalTrials.gov NCT07320677